Citius Pharmaceuticals, Inc.CTXRNASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P44
Within normal range
vs 3Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | -9.49% |
| Q3 2025 | -119.75% |
| Q2 2025 | -19.10% |
| Q1 2025 | 3.94% |
| Q4 2024 | 20.07% |
| Q3 2024 | 29.34% |
| Q2 2024 | -7.47% |
| Q1 2024 | -26.90% |
| Q4 2023 | 9.78% |
| Q3 2023 | 29.04% |
| Q2 2023 | -22.02% |
| Q1 2023 | -62.78% |
| Q4 2022 | 23.81% |
| Q3 2022 | 17.89% |
| Q2 2022 | 20.21% |
| Q1 2022 | -107.79% |
| Q4 2021 | 16.80% |
| Q3 2021 | -15.91% |
| Q2 2021 | -12.93% |
| Q1 2021 | 55.34% |
| Q4 2020 | -184.85% |
| Q3 2020 | 15.87% |
| Q2 2020 | 10.67% |
| Q1 2020 | 12.64% |
| Q4 2019 | -75.91% |
| Q3 2019 | 17.46% |
| Q2 2019 | 8.50% |
| Q1 2019 | -78.34% |
| Q4 2018 | 13.82% |
| Q3 2018 | -11.51% |
| Q2 2018 | 45.57% |
| Q1 2018 | -69.04% |
| Q4 2017 | 28.82% |
| Q3 2017 | -42.75% |
| Q2 2017 | -191.34% |
| Q1 2017 | 37.28% |
| Q4 2016 | 25.59% |
| Q3 2016 | 31.03% |
| Q2 2016 | -192.97% |
| Q1 2016 | -25.44% |